Loading...
Market
Story
Novo Nordisk Launches Wegovy in China at Fraction of US Price
Nov 18, 2024, 01:15 PM
Novo Nordisk has launched its popular obesity drug Wegovy in China, marking a significant milestone in the company's expansion in Asia. The drug will be sold at a fraction of the price it commands in the US. Initial prescriptions will roll out in Shanghai this week. This move positions Novo Nordisk to tap into China's rising demand for obesity treatments, unlocking a fast-growing market for its blockbuster franchise. China is the world's second-largest pharmaceuticals market.
View original story
Similar markets
Under 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Over 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Above 50% • 25%
30%-50% • 25%
10%-30% • 25%
Below 10% • 25%
< $500 million • 33%
$500 million - $1 billion • 33%
> $1 billion • 34%
< 1 million • 33%
1 - 2 million • 33%
> 2 million • 34%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Less than 30% • 25%
30% to 40% • 25%
40% to 50% • 25%
More than 50% • 25%
Less than 25% • 25%
25-35% • 25%
35-45% • 25%
More than 45% • 25%
Zepbound gains >10% market share over Wegovy • 25%
Zepbound gains 0-10% market share over Wegovy • 25%
Wegovy maintains current market share • 25%
Wegovy gains market share over Zepbound • 25%
Novo Nordisk • 34%
Eli Lilly • 33%
Other • 33%